Summary of GRADE profile 6Imaging (combination tests): other imaging tests (combination)

Study characteristicsSummary of findings
No. of studiesNo. of patientsPre-test probabilitySensitivity
(%)
Specificity
(%)
Post-test probability
(+ve)
Post-test probability
(despite [-ve])
Youden indexGRADE quality
99mTc-MDP-labelled scintigraphy + In-WBC
2
[K, Pa]
25 & 390.40 & 0.38Range:
80 to 100
Range:
79 to 80
Range:
0.73 to 0.75
Range:
0.0 to 0.14
Range:
0.60 to 0.79
Low
99mTc-labelled monoclonal antigranulocyte antibody + 99mTc-MDP-labelled scintigraphy
1
[Pa]
250.4090
(55 to 100)
67
(38 to 88)
0.640.090.50Low
99mTc-MDP-labelled scintigraphy + 99mTc-HMPAO-labelled scintigraphy
1
[Po]
830.4993
(80 to 96)
98
(87 to 100)
0.970.070.91Low
99mTc-MDP-labelled scintigraphy + Gallium 67 citrate
1
[We]
220.7369
(41 to 89)
83
(36 to 100)
0.920.500.52Low

[K] = Keenan (1989): reference standard = culture and/or histological examination

[Pa] = Palestro (2003): reference standard = bone biopsy and culture or clinical follow-up

[Po] = Poirer (2002): reference standard = radiological examination or histopathological analysis

[We] = Weinstein (1993): reference standard = histological examination

99mTc = technetium-99m.

From: 3, Evidence review and recommendations

Cover of Diabetic Foot Problems
Diabetic Foot Problems: Inpatient Management of Diabetic Foot Problems.
NICE Clinical Guidelines, No. 119.
Centre for Clinical Practice at NICE (UK).
Copyright © 2011, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.